CEO SUMMARY: Armed with FDA premarket approval, Cytyc must now overcome significant obstacles to introduce its ThinPrep Pap smear system into widespread clinical usage. ANOTHER WELL-FINANCED competitor will soon enter the Pap smear marketplace. Cytyc Corporation is offering 3,000,000 shares to the public with the goal of raising $48.2 million. Cytyc will use $25 million […]
- "The Dark Index"
Cytyc Corp. Raising $48 Million To Fund ThinPrep Sales Effort
- By Robert Michel
- > From the Volume IV No. 2 - January 27, 1997 Issue
